Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/17930
Title: | Cost-effectiveness of gemcitabine versus PEGylated liposomal doxorubicin for recurrent or progressive ovarian cancer: comparing chemotherapy with nanotherapy | Authors: | BOSETTI, Rita Ferrandina, Gabriella MARNEFFE, Wim Scambia, Giovanni VEREECK, Lode |
Issue Date: | 2014 | Source: | NANOMEDICINE, 9 (14), p. 2175-2186 | Abstract: | This article examines the cost-effectiveness of chemotherapy (gemcitabine) versus nanotherapy (PEGylated liposomal doxorubicin) in the treatment of ovarian cancer. Significant differences in costs were mainly due to the initial drug costs, which were €1285.28 in favor of chemotherapy. These costs were more than offset by hospitalization costs, which were €2670.21 in favor of the nanotherapy. The cost per quality-adjusted life week (QALW) for the nanotherapy was estimated to be €220.92/QALW for the base case and ranged from €170-318/QALW based on model assumptions. The clinical benefit associated with nanotherapy was achieved, yielding not only positive cost-effectiveness results, but also, surprisingly, financial savings. Although more studies are necessary, this first comprehensive analysis supports the further use of nanotherapy for ovarian cancer. | Notes: | Bosetti, R (reprint author), Hasselt Univ, Dept Appl Econ, Martelarenlaan 42 BE3500, Hasselt, Belgium. rita.bosetti@uhasselt.be | Keywords: | PEGylated liposomal doxorubicin; chemotherapy; cost–effectiveness; gemcitabine; nanotherapy; ovarian cancer; quality of life | Document URI: | http://hdl.handle.net/1942/17930 | Link to publication/dataset: | http://www.ncbi.nlm.nih.gov/pubmed/25405795 | ISSN: | 1743-5889 | e-ISSN: | 1748-6963 | DOI: | 10.2217/nnm.14.150 | ISI #: | 000345285700010 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2015 |
Appears in Collections: | Research publications |
Show full item record
SCOPUSTM
Citations
6
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
7
checked on Sep 12, 2024
Page view(s)
56
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.